Aiosyn’s NephroPath GlomeruCount introduces AI-powered kidney image analysis to Sectra Amplifier Marketplace
Figure 1. Identification and analysis of healthy and sclerotic glomeruli in a renal biopsy using NephroPath GlomeruCount.
NIJMEGEN, the Netherlands – Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for kidney disease and breast cancer, has integrated its glomerular quantification algorithm with Sectra’s diagnostic application for pathology. As the first solution for kidney biopsy analysis featured on Sectra Amplifier Marketplace, NephroPath GlomeruCount* allows kidney pathology laboratories to boost the efficiency of tissue evaluations.
GlomeruCount is part of the NephroPath platform, Aiosyn’s suite of AI-powered computational pathology algorithms designed for precise kidney lesion quantification. NephroPath’s AI quantification tools offer faster, more reproducible, and more detailed scoring of renal pathology biomarkers compared to traditional assessments.
“The introduction of NephroPath GlomeruCount to the Sectra Amplifier Marketplace is a great step forward in renal pathology. As the first AI solution for kidney biopsy analysis on the Sectra platform, it paves the way for more deep-learning algorithms that provide assessments of renal histological biomarkers. Our goal with NephroPath’s technology is to provide quantitative kidney tissue assessments and drive advancements in kidney disease research and diagnosis.” – Thomas de Bel, NephroPath product lead.
Glomeruli evaluation is important for the quality assessment of renal tissue samples. GlomeruCount is a modular and flexible software solution that integrates with existing digital pathology systems, aiding renal pathologists in the localization and counting of glomeruli. Available through cloud deployment and on-premise installation, it delivers accurate counts of healthy and sclerotic glomeruli, providing additional insights such as total areas to enhance quantitative analysis during kidney biopsy assessment.
With its inclusion on the Sectra platform, NephroPath GlomeruCount is now accessible to pathology labs worldwide, allowing efficient and consistent glomerulosclerosis analyses. Aiosyn continues to expand its portfolio of deep learning algorithms and remains committed to integrating these solutions into standard imaging platforms, such as Sectra’s.
*Note: NephroPath GlomeruCount is currently designated for Research Use Only.
About Aiosyn
Based in the Netherlands, Aiosyn develops precision pathology software for kidney disease and breast cancer, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.
About Sectra Amplifier Marketplace
The Sectra Amplifier Marketplace is a curated storefront showcasing AI applications and aims to accelerate the adoption of AI into clinical practice. The AI applications available in the Sectra Amplifier Marketplace can be integrated with Sectra’s enterprise imaging solution.
SOURCE: Aiosyn
